Carbon Accounting for Healthcare Companies in Europe

European healthcare organizations - from multinational pharmaceutical giants like Roche, Novartis, AstraZeneca, and Sanofi to regional hospital systems - now face mandatory carbon accounting under the Corporate Sustainability Reporting Directive (CSRD). Understanding your emissions landscape is no longer optional. It's a regulatory requirement that directly impacts competitive positioning, investor relations, and operational strategy.

European Healthcare Emissions Landscape Under CSRD

The healthcare sector represents one of Europe's most complex industries for carbon accounting. Pharmaceutical manufacturers, hospital networks, and medical device suppliers all generate significant emissions across their value chains - yet measurement standards remain inconsistent across organizations.

Why Healthcare Emissions Matter in Europe

European healthcare accounts for approximately 8% of regional carbon emissions when accounting for Scope 1, 2, and 3 activities combined. The sector's fragmentation - with thousands of independent hospitals, clinics, and smaller pharmaceutical suppliers - means standardized reporting through CSRD creates both compliance pressure and operational clarity. Organizations like Roche and Novartis are already leading in transparent disclosure, setting benchmarks that regulators now expect industry-wide.

The Regulatory Shift

CSRD applies to large European healthcare organizations starting in 2026 financial year reporting (with 2025 being the transition phase). This means your 2025 operational data - whatever you collect now - directly feeds your first mandatory double materiality assessment and carbon baseline.

Key Emission Sources in European Healthcare

Healthcare emissions don't follow a single profile. A pharmaceutical manufacturing plant, a major hospital system, and a medical device supplier each face distinct emissions challenges.

Pharmaceutical Manufacturing Emissions

Scope 1 and 2 emissions in pharmaceutical manufacturing stem primarily from:

• Process emissions (chemical reactions, fermentation, synthesis) - often the largest contributor
• Solvent use and recovery systems - particularly in fine chemical and active pharmaceutical ingredient (API) production
• Steam and energy generation for purification and drying processes
• Direct facility heating and fugitive emissions from equipment

Scope 3 emissions extend into raw material sourcing, particularly specialty chemical precursors where supplier carbon intensity varies dramatically across geographies.

Anaesthetic Gas Emissions

Volatile anaesthetic agents (sevoflurane, isoflurane) and nitrous oxide represent a disproportionate climate impact. Nitrous oxide carries a global warming potential (GWP) of 273 over a 100-year horizon - meaning a single kilogram equals 273 kilograms of CO2 equivalent. Even a mid-sized hospital system administering hundreds of surgical procedures annually accumulates substantial Scope 1 emissions from anaesthetics alone. These gases require specific metering to isolate and quantify.

Clinical Waste and Incineration

Incineration of infectious waste, sharps, and pharmaceutical residues generates both direct combustion emissions (Scope 1) and indirect emissions from waste transportation. High-temperature incineration of hazardous pharmaceutical waste is unavoidable in many jurisdictions, making this a baseline emissions source rather than a reduction opportunity.

Medical Device and Supply Chain Emissions

Scope 3 dominates healthcare supply chains. A hospital sourcing surgical instruments, diagnostic equipment, imaging devices, and consumables from global suppliers accumulates substantial upstream emissions. Single-use medical plastics, sterilization packaging, and cold-chain logistics for biopharmaceuticals drive significant Scope 3 footprints.

CSRD Compliance Requirements for European Healthcare

Under CSRD, healthcare organizations must report using the European Sustainability Reporting Standards (ESRS). Two standards directly shape your carbon accounting:

ESRS E1 - Climate Change

ESRS E1 requires disclosure of:

• Absolute Scope 1, 2, and 3 greenhouse gas emissions
• Intensity metrics (emissions per unit revenue, per patient, per product)
• Science-based targets or transition plans aligned with European Green Deal objectives
• Climate scenario analysis for financial impacts

ESRS S1 - Own Workforce

Alongside climate disclosure, ESRS S1 mandates health and safety metrics for employees exposed to occupational hazards - including those managing anaesthetic gases, hazardous pharmaceuticals, or infectious waste. This links carbon reduction initiatives to occupational health improvements (e.g., inhaler switches reducing exposure to propellants).

EU Green Deal and Healthcare Sustainability Initiatives

The EU Green Deal sets a binding 2050 net-zero target. Member states are developing healthcare-specific decarbonization roadmaps, including:

• Renewable energy mandates for hospital campuses (targeting 80% renewable power by 2030)
• Phased elimination of high-GWP anaesthetic gases
• Sustainable pharmaceutical manufacturing standards
• Circular economy requirements for medical device packaging

Leading European healthcare systems in Germany, France, and Scandinavia have already committed to net-zero operations by 2030-2035, creating competitive pressure across the sector.

Practical Carbon Reduction Strategies

Inhaler Reformulation: pMDI to DPI Transition

Pressurized metered-dose inhalers (pMDIs) use hydrofluorocarbon propellants with GWP values of 1,000-3,000. Dry powder inhalers (DPIs) eliminate propellants entirely, reducing per-unit emissions by up to 90%. For pharmaceutical manufacturers, this Scope 1 reduction is measurable and material.

Renewable Energy for Laboratories and Hospitals

On-site solar installations and power purchase agreements (PPAs) with renewable generators directly reduce Scope 2 emissions. Many European hospitals operate 24/7, making renewable sourcing more complex than office settings - but feasible through grid-supplied renewable contracts.

Sustainable Packaging and Supply Chain

Transitioning from multi-layer plastic to recyclable or compostable packaging reduces Scope 3 emissions. Consolidating suppliers to those with published carbon baselines improves supply chain transparency and encourages upstream decarbonization.

Carbon Accounting and ESG Compliance

Implementing robust carbon accounting systems - like those available through platforms designed for healthcare complexity - ensures CSRD data accuracy while creating operational intelligence for reduction planning. Greenio, for example, integrates pharmaceutical manufacturing emissions models, hospital energy tracking, and supply chain databases to automate Scope 1, 2, and 3 quantification.

FAQ

Which European healthcare companies must comply with CSRD?

Organizations meeting two of three criteria - >500 employees, >50 million EUR turnover, or >25 million EUR total assets - must comply starting with 2025 financial year disclosures (reported in 2026). This includes all major pharmaceutical manufacturers, hospital networks, and medical device suppliers in the EU, UK, and EEA.

How do pharmaceutical companies measure manufacturing emissions?

Measurement combines operational data (energy consumption, solvent use, waste streams) with material balance calculations for process emissions. Many pharmaceutical manufacturers use mass balancing to estimate fugitive emissions from synthesis steps where direct metering isn't feasible. What is CSRD? outlines the methodological framework expectations.

What are the biggest Scope 3 categories for European pharma?

Purchased goods and services (raw materials, specialty chemicals, packaging) typically represent 50-70% of Scope 3 emissions. Downstream transportation and product use (patient inhalation of propellants) form secondary categories. Supply chain mapping is essential for accuracy.

How do anaesthetic gases affect a hospital's carbon footprint?

A 200-bed hospital administering 5,000-10,000 anaesthetic procedures annually can generate 50-200 tonnes of CO2e from volatile anaesthetics alone - equivalent to 10-40 passenger vehicles' annual emissions. Quantifying this requires gas scavenging system flow rates and metering protocols. Carbon Accounting for Healthcare and NHS in the UK covers hospital-specific methodologies.

Conclusion

European healthcare organizations entering 2026 with CSRD compliance obligations must establish baseline carbon accounting now. Your emissions landscape - pharmaceutical manufacturing, anaesthetic gases, clinical waste, and sprawling supply chains - requires sector-specific methodologies and rigorous data collection. Regulatory requirements align with operational efficiency gains and investor expectations. The organizations leading this transition are building competitive advantage through transparency, reduction strategy clarity, and stakeholder trust.